Ultragenyx Pharmaceutical Inc (RARE) Tuesday announced a loss for the first quarter that narrowed from last year driven by revenue growth.
The company's loss was $151.1 million or $1.57 per share, compared to a net loss of $170.7 million or $2.03 per share last year.
The company's revenue for the period rose to $139.3 million from $108.8 million last year.
Looking forward to the full year 2025, the company expects revenues of $640 million to $670 million, Crysvita revenue to be in the range of $460 million to $480 million and Dojolvi revenue to be in the range of $90 million to $100 million.
For comments and feedback: editorial@rttnews.com